Correlation of tissue inhibitor of metalloproteinase-2 with proliferative activity and patients' survival in breast cancer

被引:31
作者
Nakopoulou, L
Katsarou, S
Giannopoulou, I
Alexandrou, P
Tsirmpa, I
Panayotopoulou, E
Mavrommatis, J
Keramopoulos, A
机构
[1] Natl & Kapodistrian Univ Athens, Sch Med, Dept Pathol, GR-11527 Athens, Greece
[2] Natl & Kapodistrian Univ Athens, Sch Med, Dept Gynaecol & Obstet 1, GR-11527 Athens, Greece
关键词
breast cancer; immunohistochemistry; survival; TIMP-2; tumor growth;
D O I
10.1038/modpathol.3880486
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Tissue inhibitors of metalloproteinases (TIMPs) are endogenous regulators of matrix metalloproteinases (MMPs). They are believed to possess several distinct cellular functions, particularly the contradictory activities of inhibiting MMPs and promoting tumor cell growth. Immunohistochemistry was performed to detect TIMP-2 protein in 136 infiltrative breast carcinomas. TIMP-2 protein was analyzed in parallel with clinicopathologic features (tumor size, histologic type, nuclear and histologic grade, stage), patients' overall survival and ER, PR, Ki-67, topo IIalpha, c-erbB-2, p53 and bcl-2 proteins. Statistical analysis was performed using univariate and multivariate models analysis. Immunoreactivity for TIMP-2 was observed in cancer cells and stromal. fibroblasts in 106 (77.94%) and 104 (76.47%) of 136 cases, respectively. TIMP-2 protein expression in stromal fibroblasts showed a statistically significant inverse correlation with tumor size (P = .014). An inverse correlation was also observed between TIMP-2 epithelial immunoreactivity and nuclear and histologic grade (P = .036 and P = .007, respectively). TIMP-2 protein reactivity showed statistically significant positive associations with topo IIalpha and bcl-2 in stromal and cancer cells, respectively (P = .032 and P = .001, respectively). TIMP-2 protein expression in cancer and stromal cells was associated with better patients' overall survival (P = .002 and P = .038, respectively). When evaluated by the Cox's proportional hazard regression model, this association was further established, but only as far as TIMP-2 expression in tumor epithelium was concerned (P = .019). Our results support the multifunctional potential of TIMP-2 through its correlation on the one hand to a favorable outcome, due to its MMP inhibitory activity and on the other to topo IIalpha contributing to its growth factor activity.
引用
收藏
页码:26 / 34
页数:9
相关论文
共 50 条
  • [1] The Contribution of Tissue Inhibitor of Metalloproteinase-2 Genotypes to Breast Cancer Risk in Taiwan
    Wang, Yun-Chi
    He, Jie-Long
    Tsai, Chung-Lin
    Tzeng, Huey-En
    Chang, Wen-Shin
    Pan, Shih-Han
    Chen, Li-Hsiou
    Su, Chen-Hsien
    Lin, Jiunn-Cherng
    Hung, Chih-Chiang
    Bau, Da-Tian
    Tsai, Chia-Wen
    LIFE-BASEL, 2024, 14 (01):
  • [2] Significant Relation of Tissue Inhibitor of Matrix Metalloproteinase-2 and Its Combination With Matrix Metalloproteinase-2 to Survival of Patients With Cancer of Uterine Cervix
    Wang, Po-Hui
    Ko, Jiunn-Liang
    Yang, Shun-Fa
    Tsai, Hsiu-Ting
    Tee, Yi-Torng
    Han, Chih-Ping
    Lin, Long-Yau
    Chen, Shiuan-Chih
    Shih, Yang-Tse
    REPRODUCTIVE SCIENCES, 2011, 18 (08) : 798 - 808
  • [3] Serum metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 in lung carcinoma patients
    Drzewiecka-Jedrzejczyk, Magdalena
    Wlazel, Rafal
    Terlecka, Monika
    Jablonski, Slawomir
    JOURNAL OF THORACIC DISEASE, 2017, 9 (12) : 5306 - 5313
  • [4] Altered expression of metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 in cervical disc herniation patients
    Zhuang, H. M.
    Xu, G. T.
    Wen, S. F.
    Guo, Y. Y.
    Huang, Q.
    GENETICS AND MOLECULAR RESEARCH, 2016, 15 (02):
  • [5] Matrix metalloproteinase-2 regulates the expression of tissue inhibitor of matrix metalloproteinase-2
    Kimura, Kaoru
    Cheng, Xian Wu
    Nakamura, Kae
    Inoue, Aiko
    Hu, Lina
    Song, Haizhen
    Okumura, Kenji
    Iguchi, Akihisa
    Murohara, Toyoaki
    Kuzuya, Masafumi
    CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2010, 37 (11) : 1096 - 1101
  • [6] Plasma levels of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 correlate with disease stage and survival in colorectal cancer patients
    Waas, ET
    Hendriks, T
    Lomme, RMLM
    Wobbes, T
    DISEASES OF THE COLON & RECTUM, 2005, 48 (04) : 700 - 710
  • [7] INCREASED GELATINOLYTIC ACTIVITY IN KERATOCONUS KERATOCYTE CULTURES - A CORRELATION TO AN ALTERED MATRIX METALLOPROTEINASE-2 TISSUE INHIBITOR OF METALLOPROTEINASE RATIO
    KENNEY, MC
    CHWA, M
    OPBROEK, AJ
    BROWN, DJ
    CORNEA, 1994, 13 (02) : 114 - 124
  • [8] Increased expression of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 is correlated with poor prognostic variables in patients with thymic epithelial tumors
    Sogawa, K
    Kondo, K
    Fujino, H
    Takahashi, Y
    Miyoshi, T
    Sakiyama, S
    Mukai, K
    Monden, Y
    CANCER, 2003, 98 (09) : 1822 - 1829
  • [9] S-adenosylmethionine, a methyl donor, up regulates tissue inhibitor of metalloproteinase-2 in colorectal cancer
    Hussain, Z.
    Khan, M. I.
    Shahid, M.
    Almajhdi, F. N.
    GENETICS AND MOLECULAR RESEARCH, 2013, 12 (02): : 1106 - 1118
  • [10] Polymorphisms in the matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 and the risk of human adenomyosis
    Kang, Shan
    Zhao, Xiwa
    Xing, Huimin
    Wang, Na
    Zhou, Rongmiao
    Chen, Shucheng
    Li, Wansheng
    Zhao, Jian
    Duan, Yanan
    Sun, Donglan
    Li, Yan
    ENVIRONMENTAL AND MOLECULAR MUTAGENESIS, 2008, 49 (03) : 226 - 231